Institutional members access full text with Ovid®

Share this article on:

Tracheal replacement for primary tracheal cancer

Haag, Johannes C.; Jungebluth, Philipp; Macchiarini, Paolo

Current Opinion in Otolaryngology & Head and Neck Surgery: April 2013 - Volume 21 - Issue 2 - p 171–177
doi: 10.1097/MOO.0b013e32835e212b
HEAD AND NECK ONCOLOGY: Edited by Piero Nicolai and Cesare Piazza

Purpose of review To summarize the so far applied clinical methods of tracheal replacement, comparing pros and cons of conventional and tissue-engineered approaches.

Recent findings Several strategies have been most recently described to replace the trachea-like aortic homografts, allotransplantation, and tissue engineering. Allotransplantation requires lifelong immunosuppression and this may be ethically questioned being not a lifesaving procedure. Tissue-engineered tracheal transplantation has been clinically applied using biological or bioartificial tubular or bifurcated scaffolds reseeded with mesenchymal stromal cells, and bioactive molecules boosting regeneration and promoting neovascularization.

Summary Tracheal tissue engineering may be a promising alternative to conventional allotransplantation in adults and children. Different methods have been developed and are currently under active clinical investigation, and await long-term results.

Division of Ear, Nose, and Throat, Department of Clinical Science, Intervention and Technology (CLINTEC), Advanced Center of Translational Regenerative Medicine, Karolinska Institutet, University Hospital, Stockholm, Sweden

Correspondence to Paolo Macchiarini, MD, PhD, ACTREM, Division of Ear, Nose, and Throat (CLINTEC), Karolinska Institutet, Alfred Nobel Allé 8, Huddinge, S-14186 Stockholm, Sweden. Tel: +46 8 585 87353; e-mail:

© 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins